Samsung Bioepis Racks Up More Awards for Its Biosimilar Packaging
Medicinal packaging shouldn't remind patients that they have a condition, according to Samsung Bioepis.
Medicinal packaging doesn’t have to be harsh and strident. That’s the concept behind the biosimilar packaging for which Samsung Bioepis continues to earn international awards. Most recently, Samsung Bioepis has garnered International Forum (iF) Design Award 2021 honors for packaging.
Soft shapes and soothing mono-colors characterize the package designs for Samsung Bioepis’ drug products, which include biosimilars. The company, based in Incheon, Republic of Korea, has called its package design concept “Passion for Health—Pure Joy in Life.”
“Taking medication can be a constant reminder of the medical condition, and we wanted to remind patients of ‘pure joy’ in life when they look at our product packaging and design,” Jaywoo Kim, senior vice president and manufacturing division leader at Samsung Bioepis, said in a statement.
The company won in 2 categories: Packaging—Medicine/Pharmaceutics and Communication—Corporate Identity/Branding.
In 2020, the company won package design awards in the Red Dot competition.
Study Documents HCPs’ Experiences of a Mandatory Switch to Inform Future Transitions
December 2nd 2023A survey explores the experiences of health care providers (HCP) throughout the transition process following a mandatory switch from the adalimumab originator (Humira) to a biosimilar in New Zealand in 2022.
IQVIA Highlights Opportunity to Cash In on Biosimilars for Biologics Losing Market Exclusivity
November 29th 2023A report from IQVIA noted that Europe could miss out on €15 billion in cost savings by not having biosimilars for medications about to lose market exclusivity, shedding light on the implications for overall health care savings and ultimately, patient access.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
